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Glycolytic activity is increased in proliferating cells, leading to the concept that glycolysis could 35 
be a therapeutic target in cystic diseases and kidney cancer. Pre-clinical studies using the glucose 36 
analogue 2-deoxy-D-glucose have shown promise; however, inhibiting glycolysis in humans is 37 
unlikely to be without risks. While proximal tubules are predominantly aerobic, later segments 38 
are more glycolytic. Understanding exactly where and why glycolysis is important in the 39 
physiology of the distal nephron is thus crucial in predicting potential adverse effects of 40 
glycolysis inhibitors. Live imaging techniques could play an important role in the process of 41 
characterizing cellular metabolism in the functioning kidney. The goal of this mini-review is to 42 
briefly summarize recent findings on targeting glycolysis in proliferative kidney diseases, and to 43 
highlight the necessity for future research focusing on glycolysis in the healthy kidney.    44 
  45 
Introduction 46 
GLYCOLYSIS is the metabolic pathway that converts glucose into pyruvate, alongside this process 47 
ATP and NADH are generated. In the presence of oxygen, pyruvate is actively transported into 48 
the mitochondria and further metabolized in the tricarboxylic acid (TCA) cycle (17), which 49 
produces energy precursors for oxidative phosphorylation. In the absence of oxygen, pyruvate is 50 
converted into lactate, and glycolysis remains the main source of ATP production, so-called 51 
anaerobic glycolysis (32).  52 
Oxygen availability in the kidney decreases gradually from the cortex to the medulla, and this is 53 
associated with a difference in metabolism between the cortical and medullary nephron segments 54 
(12). Proximal tubules in the cortex perform the bulk of fluid reabsorption and are known to be 55 
highly aerobic (54), since oxidative phosphorylation is the most efficient method to generate ATP 56 
required to drive solute transport. In contrast, distal nephron segments are much more glycolytic 57 
(15, 54). In the medulla this is probably partly explained by the lower oxygen tension, but it is 58 
also possible that glycolysis might be advantageous for some specialized functions in the cortical 59 
distal nephron segments.  60 
Glycolysis is known to be upregulated in dividing cells in the normal development of the kidney 61 
(22), and similar findings have recently also been observed in proliferative kidney diseases. 62 
Glycolysis is therefore increasingly being investigated as a therapeutic target for cystic diseases 63 
and kidney cancer (6, 24, 42). However, given the importance of glycolysis in normal kidney 64 
function, inhibiting this process is not without risks. This mini-review will briefly summarize the 65 
experience to date of targeting glycolysis in proliferative kidney diseases, and will highlight the 66 
need for new research to better understand where and why glycolysis is important in the normal 67 
physiology of the distal nephron.   68 
 69 
Glycolysis in proliferative kidney diseases 70 
The “Warburg effect” 71 
In highly proliferative cells, such as cancer cells, glycolysis is typically used as energy source 72 
even when sufficient levels of oxygen are available to perform oxidative phosphorylation. This 73 
phenomenon is called aerobic glycolysis or the “Warburg effect”, initially described by Otto 74 
Warburg almost one hundred years ago (23, 50). Although not as efficient for producing ATP, 75 
glycolysis is beneficial for proliferative cells, as their energy requirements are typically low and 76 
glucose can be utilized instead for anabolic processes necessary for new cell formation (21, 23). 77 
In the following sections, we will briefly highlight two important proliferative kidney diseases, 78 
where evidence suggests glycolysis is also upregulated.  79 
 80 
Polycystic kidney disease 81 
Autosomal dominant polycystic kidney disease (ADPKD) is a chronic, inherited disorder that is 82 
characterized by fluid filled cysts originating in a minority of nephrons, and is caused by 83 
mutations in polycystin 1 (Pkd1) or 2 (Pkd2) (10, 14). Cell proliferation is one of the major 84 
factors contributing to cyst progression, and activation of cell proliferation signalling pathways 85 
has repeatedly been identified in ADPKD (18, 20, 38, 41, 49). In the last decade numerous 86 
studies have reported evidence of upregulated glycolysis in the pathogenesis of ADPKD (7, 24, 87 
31, 37, 38), and this subject has recently been comprehensively reviewed by Padovano et al. (31). 88 
Briefly, Rowe et al. were one of the first to describe an alteration in metabolism in ADPKD, and 89 
that mouse embryonic fibroblasts lacking Pkd1 rely on glycolysis as an energy source, even 90 
under aerobic conditions (38). These findings were supported by a subsequent study showing an 91 
upregulation of the glycolytic enzymes hexokinase 1 and 2 (Hk1, Hk2) and lactate dehydrogenase 92 
A (LDHa) in a rat model of ADPKD (37). Further in vivo evidence for the Warburg effect came 93 
from a Pkd1 inducible knock-out model, where an increased glucose uptake and conversion to 94 
lactate was observed, by following the 13C-labelled forms of these molecules (7). It is important 95 
to note that not all studies have detected increased glycolysis in ADPKD (26, 51). However, it 96 
seems clear that substantial changes in metabolism occur in tubular cells during cyst 97 
development, and understanding the nature of these is likely to be crucial to fully elucidating the 98 
pathogenesis.  99 
 100 
Kidney cancer 101 
Consistent with the Warburg effect, glycolysis is also thought to be upregulated in clear cell renal 102 
cell carcinoma (ccRCC) (5, 33, 34, 48, 52). This is the most common type of cancer in the 103 
kidney, and is mainly caused by a mutation in the tumour suppressor gene VHL (29, 39). The 104 
degree of shift towards glycolysis seems to be grade dependent, and is most marked in high-grade 105 
disease (5). Upregulation of glycolysis is associated with a simultaneous decrease in expression 106 
of TCA cycle genes, but an increase in genes involved in glutamine transport and fatty acid 107 
synthesis (5). These findings are likely explained by studies performed in VHL-deficient ccRCC 108 
cells, which showed that the TCA acts in reverse (so-called reductive carboxylation), using 109 
glutamine to generate citrate, which can then be exported to the cytosol to increase the production 110 
of macromolecules needed for cell proliferation (13). Interestingly, there is now evidence that his 111 
phenomenon might also occur in ADKPD (35), suggesting overlap in the disease mechanisms.  112 
 113 
Glycolysis as treatment target   114 
Given that glycolysis seems to be a crucial process in cell proliferation, it follows that inhibiting 115 
glycolysis might be beneficial in treating diseases like ADPKD and ccRCC, and numerous 116 
studies are now investigating this possibility. Aerobic glycolysis can potentially be inhibited on 117 
many levels (reviewed in (27, 31, 42, 44)), including: the uptake of glucose into the cell by 118 
glucose transporters; the breakdown of glucose to glucose-6-phosphate by hexokinase; the 119 
formation of pyruvate by pyruvate kinase; and the conversion of pyruvate to lactate by LDH. 120 
Furthermore, besides glycolysis, the increased uptake of glutamine can also be targeted to inhibit 121 
reductive carboxylation (13, 35). However, the strategy that has received most attention is direct 122 
inhibition of glycolysis with the glucose analogue 2-deoxy-D-glucose (2DG).  123 
 124 
2-deoxy-D-glucose  125 
2DG is taken up by cells and phosphorylated by hexokinase, but is not further catabolized in the 126 
glycolysis pathway (53). Although widely used in cancer biology (55), it has not yet been 127 
extensively tested in pre-clinical ccRCC models. However, a recent study using primary cell 128 
cultures from low- and high-grade ccRCC showed that 2DG significantly decreased lactate 129 
secretion and ATP levels only in the latter (2). This suggests that the usage of glycolysis 130 
inhibition as a therapy might need to be tailored to individual patients, depending on information 131 
acquired from tissue histology.  132 
Meanwhile, 2DG has also been tested in various in vitro and in vivo studies of ADPKD. 133 
Administration of 2DG significantly retarded cyst progression in two different rodent models (7, 134 
37). Furthermore, a low dose combinational treatment of 2DG with metformin (normally used for 135 
the treatment of type 2 diabetes mellitus) was shown to inhibit cell proliferation in human-136 
derived cystic kidney epithelial cells (56). This combination treatment was also tested in a 137 
miniature pig model, and was shown to markedly reduce renal cyst formation and protect renal 138 
function (19). 139 
Overall, early studies have suggested that 2DG has some promise as a therapy for proliferative 140 
kidney disease. However, glycolysis is a fundamental and widespread metabolic process in living 141 
organisms, and glucose depletion in the blood (hypoglycaemia) is known to produce serious 142 
adverse effects (43), including in the nervous, immune and respiratory systems (9, 25). Thus, 143 
intentionally inhibiting glycolysis in vivo brings significant potential risks, and careful attention 144 
needs to be given to safety issues. 145 
 146 
Safety issues with blocking glycolysis in vivo 147 
The use of 2DG has been reported in phase I clinical trials of different types of tumours and 148 
generally it seems to be surprisingly well tolerated (36, 43, 45). Therefore, it should be possible 149 
to implement its use in clinical trials of ADPKD patients (reviewed in (24)). However, the safety 150 
profile of this compound, together with the appropriate dose, needs to be more carefully 151 
determined. While some animal studies report no degree of toxicity over prolonged periods of 152 
administration of 2DG (7, 30), others have described severe adverse cardiac effects (28, 46). 153 
Moreover, cardiac abnormalities, together with disorientation, tiredness, and excessive sweating 154 
have also been observed in the human clinical trials (36, 45).  155 
 156 
Finding a treatment regime that produces sufficient blockade of glycolysis in proliferating cells to 157 
substantially retard disease progression, but without adversely altering metabolism in healthy 158 
tissues, represents a major logistical challenge. This concept is particularly pertinent to the 159 
kidney, where levels of glycolysis are normally quite high in the medulla (Figure 1A). Moreover, 160 
besides producing ATP, glucose is also important for other metabolic processes, such as the 161 
generation of NAD(P)H via the pentose phosphate pathway. Indeed, we recently found that 162 
administration of 2-DG acutely decreases mitochondrial and cytosolic NAD(P)H signals in 163 
proximal tubules (4).  164 
Thus, while inhibiting glycolysis could be of benefit in retarding the progression of kidney cysts 165 
and tumours, side effects might arise, partly due to a loss of normal specialized functions in distal 166 
nephron segments. To understand the nature and magnitude of these effects, it will first be 167 
necessary to pin-point which cell types and transport processes are particularly dependent on 168 
glycolysis. This in turn will necessitate the development of new techniques to study cellular 169 
metabolism in intact functioning kidney tissue.    170 
 171 
Glycolysis in the distal nephron segments 172 
Within the distal nephron, previous studies have suggested that the collecting duct (CD) is the 173 
site with the highest glycolytic activity. CDs express more glycolytic enzymes than other 174 
segments (15), generate more lactate (1), and maintain ATP levels better when aerobic respiration 175 
is inhibited (47). Unlike other segments, CDs comprise of two very different cell types 176 
interspersed with each other, which have very distinct transport functions. Principal cells (PCs) 177 
are responsible for sodium and water homeostasis, whereas intercalated cells (ICs) maintain an 178 
acid-base balance (8). In parallel with transport functions, it is likely that PCs and ICs also 179 
display differences in metabolism. However, relatively little is known about this, due to the 180 
technical challenges of isolating cells in an appropriate state to perform standard metabolic 181 
assays. Thus, most studies have historically considered the CD as a single entity, and it therefore 182 
remains unclear which cell type is predominantly responsible for the overall glycolytic 183 
phenotype, and also which specific transport processes might be dependent on glycolysis.  184 
Morphological studies such as electron microscopy reveal major differences in ultrastructure 185 
between cells in the CD. Of relevance to metabolism, the density of mitochondria is much higher 186 
in ICs than in PCs (3) (Figure 1B), perhaps hinting that the latter might be more glycolytic. 187 
However, mitochondria have important functions other than generating ATP, so it does not 188 
necessarily follow that ICs generate more ATP via oxidative phosphorylation.  189 
The development of high-resolution live imaging techniques like multiphoton microscopy 190 
provides a potential new avenue to study cellular metabolism in living animals (16, 40). Using 191 
this approach, it has recently been described that cells in the rat CD display striking differences in 192 
the uptake of mitochondrial dyes, hinting at the existence of major differences in metabolism 193 
between PCs and ICs (11). We have also observed similar signal patterns in mice (Figure 1C), 194 
and are currently utilizing multiphoton microscopy - in parallel with other imaging techniques - 195 
to try to further understand the significance of these findings, and what they might tell us about 196 
the nature of metabolism along the CD. We envisage that such an approach could finally shed 197 
some light on the relationship between glycolysis and transport function in the distal nephron, 198 
understanding of which could be crucial in anticipating adverse effects of glycolysis inhibitors.  199 
 200 
Conclusion 201 
Glycolysis is upregulated in proliferating cells and has thus been identified as a novel therapeutic 202 
target in ADPKD and kidney cancer. Pre-clinical studies with blocking agents such as 2DG have 203 
shown some promise, but inhibiting glucose metabolism in humans is unlikely to be without risk. 204 
In particular, glycolytic activity is thought to be high in segments like the CD. It is therefore 205 
crucial to further elucidate where and why glycolysis is important in the nephron, and live cell 206 
imaging techniques could play an important role in this process.   207 
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Figure legends 383 
Figure 1: Glycolysis in the kidney and heterogeneity of the collecting duct. (A) The oxygen 384 
gradient in the kidney decreases gradually from the cortex to the medulla, and glycolytic activity 385 
is higher in the latter. (B) Electron microscopy of a cortical collecting duct (CD), showing that 386 
intercalated cells (ICs) have a much higher mitochondrial density than neighboring principal cells 387 
(PCs). (C) In vivo multiphoton imaging of a mouse kidney reveals a heterogeneous uptake along 388 
the cortical CD of the voltage dependent mitochondrial dye Tetramethylrhodamine (TMRM) 389 
(red). TMRM signal intensity provides a readout of mitochondrial energization within living 390 
cells, which is dependent on respiratory chain activity. Scale bar = 5 μm (A) and 10 μm (C). 391 
Schematic image was produced using scientific illustration toolkits from Motifolio.  392 
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